FDA recognized this disconnect and issued its Computer Software Assurance (CSA) draft guidance in 2022, formally replacing the earlier General Principles of Software Validation guidance from 2002. CSA does not eliminate computer system validation. It redirects validation effort toward activities that meaningfully reduce risk rather than toward documentation volume that satisfies auditors but protects no one.

This guide covers what CSA requires, how it differs from traditional computer system validation (CSV), and how to implement a risk-based validation program that satisfies FDA while reducing the burden on quality teams.

What CSA is and what changed from the 2002 guidance

The FDA’s 2022 CSA draft guidance establishes a risk-based framework for assuring that computer systems used in regulated pharmaceutical and device manufacturing perform as intended. The core shift is this: validation effort should be proportional to the patient risk associated with the system, and it should focus on critical thinking and testing rather than on producing documentation for its own sake.

Under the old 2002 guidance, organizations interpreted “validation” as a documentation exercise. The common result was validation packages with thousands of pages of pre-approved test scripts, executed line by line, generating execution records that demonstrated procedure-following but rarely uncovered actual system defects. CSA frames this as wasted effort that could more productively go toward genuine risk analysis and targeted testing of functions that matter.

The 2022 CSA guidance introduces several important concepts:

• Intended use drives scope: Validation scope is defined by how the system is used in your regulated context, not by all features the software contains. A laboratory information management system used only to track sample status requires validation of the sample tracking function, not every feature in the software.
• Supplier leverage is expected: Organizations are expected to leverage supplier documentation, testing, and quality evidence rather than repeating all testing themselves. Supplier audit results, software development lifecycle documentation, and factory acceptance testing records all contribute to your validation evidence.
• Testing should be risk-based and scripted versus unscripted based on risk: High-risk functions require scripted, pre-approved testing with recorded execution. Lower-risk functions may be verified through unscripted exploratory testing by qualified users, which FDA explicitly permits under CSA.
• Audit trails remain non-negotiable: Regardless of system risk level, any system that creates, modifies, or deletes regulated records must maintain a complete audit trail. CSA does not relax 21 CFR Part 11 requirements.

The CSA risk-based framework in practice

Implementing CSA requires applying structured risk thinking at two levels: system-level categorization and function-level risk assessment.

System-level categorization

The first step in a CSA-based validation program is categorizing each computer system based on its intended use and its connection to patient risk. FDA’s guidance distinguishes between systems that directly affect product quality and patient safety, systems that create or manage regulated records, and systems that are used in regulated operations but have limited direct patient risk impact.

A manufacturing execution system that controls process parameters in a GMP batch is a high-risk system. An inventory management system used to track non-critical office supplies is not subject to validation at all. A quality management system that stores batch records and deviation investigations falls in between, with specific functions (audit trail, access control, record integrity) requiring documented validation evidence and lower-risk features requiring less.

Function-level risk assessment

Once the system category is established, the validation team identifies the specific functions used in regulated activities and assigns a risk rating to each. The risk rating is based on three questions: What is the probability that this function will fail? If it fails, what is the severity of the impact on product quality or patient safety? Is there a detection mechanism that would catch the failure before it affects regulated activities?

Functions rated high risk require scripted, pre-approved test protocols executed by qualified testers with recorded results. Functions rated low risk can be verified through unscripted testing or by leveraging supplier qualification evidence. Functions that are not used in regulated activities are out of scope entirely.

Step-by-step CSA implementation

Step 1: Define the intended use

Write a clear intended use statement for the system that describes what it does, who uses it, and how it connects to regulated activities. This statement defines the scope of everything that follows. If the intended use is defined too broadly, the validation becomes unnecessarily large. If it is too narrow, FDA may ask about functions that were excluded without justification.

Step 2: Identify and evaluate the supplier

Evaluate the software supplier’s development practices, testing documentation, and quality management system. A supplier with a mature software development lifecycle and comprehensive factory acceptance testing documentation provides evidence you can use directly in your validation package, reducing the amount of testing your organization needs to perform. Document your supplier evaluation with the criteria used and the conclusions reached.

Step 3: Conduct a system risk assessment

Perform a risk assessment at the function level, documenting each function, its intended use in your regulated context, the risk rating, and the rationale for that rating. This risk assessment is the backbone of the entire validation program. It determines which functions get scripted testing, which get unscripted testing, and which rely primarily on supplier evidence.

Step 4: Develop a validation plan

The validation plan describes the scope, approach, roles and responsibilities, and deliverables for the validation. Under CSA, the plan should explicitly state which functions are in scope, which testing approach applies to each (scripted vs. unscripted), what supplier evidence will be leveraged, and how validation will be maintained over the system’s lifecycle.

Step 5: Execute testing appropriate to the risk level

Execute scripted protocols for high-risk functions. Protocols must be pre-approved before execution, executed by qualified personnel, and deviations from the protocol must be documented and resolved before the protocol is closed. For low-risk functions, perform unscripted testing by qualified users who document what they tested and the results they observed. Capture screenshots, system-generated logs, or other objective evidence of testing.

Step 6: Manage deviations and failures

Any deviation from a scripted test protocol or any failure observed during unscripted testing must be documented, assessed for patient risk impact, and resolved before the system is accepted for regulated use. Resolution may require working with the supplier to correct a defect, or it may involve a workaround and a documented risk acceptance if the issue is minor and the risk is acceptably low.

Step 7: Complete the validation summary and accept the system

The validation summary consolidates all evidence gathered — supplier qualification, risk assessment, test execution records, deviation resolutions — and documents the conclusion that the system is suitable for its intended use. This document, signed by the validation team and quality unit, formally accepts the system for regulated use.

Step 8: Maintain validation through the system’s lifecycle

CSA does not end at initial deployment. Changes to the system, its configuration, or its intended use trigger a change control process that evaluates whether revalidation is required and to what extent. Periodic reviews confirm that the system continues to perform as intended. Audit trail reviews should be scheduled and documented on a defined frequency.

Common CSA implementation mistakes

Treating CSA as a documentation reduction exercise only. CSA reduces unnecessary documentation, but it increases the expectation that the documentation that does exist is genuinely thoughtful. Risk assessments that assign every function a “medium” risk without clear rationale, or validation plans that repeat boilerplate language without connecting it to the specific system and intended use, will not satisfy FDA reviewers.

Underestimating supplier qualification requirements. Leveraging supplier evidence requires actually evaluating the supplier’s quality system and documentation. A supplier qualification that consists of downloading a certificate from the vendor’s website is insufficient. The evaluation must assess development practices, testing rigor, and the supplier’s own quality management.

Forgetting legacy systems. CSA applies to new systems. Organizations with legacy systems validated under the old approach do not need to retroactively revalidate using CSA, but any significant changes to those systems should be managed using risk-based CSA principles going forward.

How Cloudtheapp supports computer system validation

Cloudtheapp is built on a fully validated platform that includes a comprehensive validation package for every software update, delivered to customers at no additional cost. The platform conforms to FDA computer system validation guidelines and provides the IQ, OQ, and PQ documentation that regulated manufacturers need to support their own validation activities.

For organizations managing their internal computer system validation program, Cloudtheapp’s quality management suite includes validation management workflows that support the CSA framework: risk assessments, test protocol authoring and execution tracking, deviation management, and validation summary generation. With 60+ applications and a no-code configuration environment, Cloudtheapp can be adapted to match your specific validation SOPs without custom software development. Schedule a demo to see the validation management capabilities in practice.

Conclusion

FDA’s CSA guidance does not make computer system validation optional. It makes it smarter. By focusing validation effort on the functions that actually matter for patient safety and product quality, and by explicitly permitting organizations to leverage supplier evidence and unscripted testing for lower-risk functions, CSA allows quality teams to spend less time generating paper and more time doing the risk thinking that genuine quality assurance requires. Organizations that implement CSA well will find that their validation packages are smaller, more defensible, and faster to complete than anything produced under the old documentation-first approach.

This post created by and appeared first on Cloudtheapp

For quality managers implementing or evaluating electronic quality management systems, document management platforms, laboratory information management systems (LIMS), or electronic batch records, Part 11 compliance is not optional. FDA inspectors cite Part 11 deficiencies regularly, and the consequences range from warning letters requiring costly remediation to import alerts that halt product distribution.

This checklist covers the core requirements of 21 CFR Part 11, organized by compliance area, with practical implementation guidance for each requirement.

Scope: when 21 CFR Part 11 applies

Part 11 applies to electronic records that FDA regulations require a company to create or maintain, and to electronic signatures applied to those records. It does not apply to records that companies choose to maintain electronically but that are not FDA-required. However, FDA’s predicate rule requirements, specifically the underlying regulations that require specific records in the first place, remain in effect regardless of the format in which records are kept.

Systems that typically fall within Part 11 scope in regulated life sciences companies include:

Electronic quality management systems (eQMS) managing SOPs, CAPAs, deviations, and change control records

Electronic batch records for pharmaceutical manufacturing

Laboratory information management systems storing analytical test results

Electronic document management systems for controlled documents

Electronic training management systems tracking employee qualification

Computerized manufacturing execution systems (MES) generating production records

Clinical trial management systems for FDA-required study records

FDA’s 2003 guidance on Part 11 scope and application clarified that the agency intends to take a risk-based approach to enforcement, focusing on records and signatures whose integrity is most critical to product safety. This guidance reduced the compliance burden for lower-risk records but did not eliminate Part 11 requirements for records whose accuracy and integrity directly affect patient safety and product quality decisions.

Section 11.10: controls for closed systems

The majority of Part 11’s substantive technical requirements appear in section 11.10, which covers closed systems: systems where access is controlled by the owner of the system. Most enterprise eQMS platforms are closed systems under this definition.

Validation (11.10(a))

Systems used to create, modify, maintain, archive, retrieve, or transmit electronic records must be validated to ensure accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records. Computer system validation (CSV) under FDA’s Computer Software Assurance (CSA) guidance provides the framework for meeting this requirement.

Checklist items:

Validation plan or CSA risk assessment exists and is approved

User requirements specifications document intended system use and critical functions

Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) protocols are executed and approved

Validation summary report is approved by quality management

Periodic review schedule is defined and executed

System changes go through a documented change control and impact assessment process

Audit trail (11.10(e))

Systems must use computer-generated, time-stamped audit trail records to independently record the date and time of operator entries and actions that create, modify, or delete electronic records. Audit trails must be retained for a period at least as long as required for the subject electronic records and must be available for agency review and copying.

Checklist items:

Audit trails are system-generated and cannot be modified or deleted by regular users

Each audit trail entry captures: user identity, timestamp (date and time), nature of the action (create, modify, delete), and the original and new value for modified fields

Audit trail retention period matches or exceeds the retention requirement for the associated records

Audit trails are reviewed periodically as part of quality oversight activities

Audit trails are accessible for FDA inspection and can be exported in human-readable format

FDA inspectors frequently check audit trail integrity during inspections of electronic systems. The most common finding is an audit trail that exists but is not routinely reviewed; Part 11 requires both the existence of audit trails and periodic review of those trails to detect unauthorized changes.

System access controls (11.10(d))

Systems must limit access to authorized individuals. Access control is fundamental to the integrity of electronic records: if unauthorized users can create, modify, or delete records, the records cannot be considered trustworthy.

Checklist items:

Each user has a unique username; shared accounts are prohibited

Access levels are role-based and reflect the principle of least privilege: users have access only to the functions their role requires

A formal user access management process exists for granting, modifying, and revoking access

Access rights are reviewed periodically, typically annually, to identify inactive accounts and inappropriate access levels

Account lockout is configured after a defined number of failed login attempts

Procedures address what happens when an employee’s access must be revoked immediately (e.g., termination)

Operational system checks (11.10(f)) and authority checks (11.10(g))

Systems must use operational system checks to enforce sequencing of steps and events appropriate to the records. Authority checks must ensure that only authorized individuals can use the system, electronically sign records, access the operation or device, or perform operations at hand.

Checklist items:

Workflow enforcement prevents steps from being completed out of sequence where required (e.g., review cannot occur before authoring is complete)

Electronic signature permissions are tied to role-based authority; a reviewer cannot sign records they authored where separation of duties is required

The system enforces that only users with the appropriate role can approve specific document types or record categories

Device checks (11.10(h)) and documentation (11.10(k))

Systems must use device checks, where applicable, to determine the validity of the source of data input or operational instructions. Documentation of policies and procedures covering system use, security, and electronic signature use must be maintained.

Checklist items:

SOPs exist for system use, including electronic signature application procedures

SOPs address what to do when system access is compromised (e.g., password sharing discovered, unauthorized access detected)

SOPs address record retention and archival for electronic records

All SOPs are controlled under the organization’s document management system

Section 11.50 and 11.70: electronic signature requirements

Electronic signatures under Part 11 are not simply typed names or checkboxes. They are binding computer-based equivalents of handwritten signatures that must meet specific technical and procedural requirements to be legally and regulatorily valid.

Signature components (11.50)

Each electronic signature must display: the printed name of the signer, the date and time when the signature was executed, and the meaning associated with the signature (e.g., “Authored by,” “Reviewed by,” “Approved by”).

Checklist items:

All electronically signed records display the signer’s full name, timestamp, and signature meaning

Signature display is part of the record itself, visible when the record is printed or exported

Records cannot be signed by anyone other than the authenticated user (no signing on behalf of another user using their credentials)

Electronic signature linking (11.70)

Electronic signatures must be linked to their respective records in a manner that cannot be excised, copied, or otherwise transferred to falsify an electronic record. This prevents copying a signature from one record and applying it to another.

Checklist items:

Electronic signatures are cryptographically or technically linked to the specific record they sign

Signature integrity can be verified; a modified record does not retain a valid prior signature

System documentation confirms the technical mechanism by which signatures are linked to records

Section 11.100 and 11.200: signature identification and controls

Unique identification (11.100)

Each electronic signature must be unique to one individual and must not be reused or reassigned to anyone else. Prior to granting use of electronic signatures, organizations must certify to FDA that the electronic signatures used are intended to be legally binding, the same as handwritten signatures.

Checklist items:

Each electronic signature is uniquely assigned to one individual

Username/password combinations (or biometric identifiers) are never shared between individuals

The organization has submitted the required certification to FDA (21 CFR 11.100(c)): a one-time submission certifying that electronic signatures used are legally binding

New employees receive training on the legal equivalence of electronic signatures before being authorized to sign electronic records

Signature components for non-biometric signatures (11.200(a))

Non-biometric electronic signatures, specifically username and password combinations, which are the most common type in eQMS platforms, must employ at least two distinct identification components. For transactions performed at a workstation in a continuous session, only the first signing event requires both components; subsequent signings in the same session require only one component (typically the password).

For transactions not performed at a workstation during a single continuous session, for example, when a user signs a record and then walks away from the system, both components are required for each signing action.

Checklist items:

Electronic signatures require a minimum of two identification components (e.g., username + password)

Session timeout is configured to require re-authentication after a defined period of inactivity

After session timeout, the full two-factor authentication is required before a signature can be applied

Password complexity and expiration requirements are enforced by the system

Record retention and availability

Part 11 requires that electronic records be protected to enable accurate and ready retrieval throughout the required retention period. This extends to archived records: the archive must be readable and searchable for the duration of the retention period, even if the original software system is replaced.

Checklist items:

Electronic records are backed up regularly, with backup procedures documented and tested

Long-term archive strategy is documented; records remain accessible in human-readable format for the full retention period

Migration plans exist for when systems are decommissioned, so records are exported and preserved in formats that will remain accessible

Disaster recovery procedures address restoration of electronic records after system failure

Record retention schedule aligns with applicable FDA regulations (e.g., 21 CFR Part 211.68, 21 CFR Part 820.180)

Common Part 11 inspection findings

Understanding the most frequently cited Part 11 deficiencies helps quality teams prioritize their compliance review efforts.

Shared user accounts. Using shared logins, meaning a single account used by multiple people, violates the unique identification requirement and makes audit trails meaningless because the system cannot identify which individual took a specific action. This is one of the most common and most serious Part 11 findings because it undermines the integrity of every electronically signed record in the system.

Unreviewed audit trails. Many organizations have systems with audit trail capability that is technically enabled but never reviewed. FDA expects audit trails to be reviewed as part of quality oversight; the frequency and scope of review should be documented in a procedure. An audit trail that no one reads does not fulfill the purpose of the requirement.

Unvalidated system changes. Software updates, configuration changes, and new module deployments that proceed without impact assessment and validation documentation violate section 11.10(a). The most common scenario is a vendor-pushed software update that the organization does not evaluate for Part 11 impact before allowing it to affect a production system.

Missing or inadequate SOPs. Part 11 requires written policies and procedures covering electronic record and signature controls. Systems without accompanying SOPs, or with SOPs that do not address the specific system, lack the procedural foundation that FDA expects to see during inspections.

Inadequate training records. Users of systems covered by Part 11 must be trained on the legal significance of electronic signatures and on the organization’s policies for electronic record management. Training records demonstrating this training must exist and must be current for all active system users.

Part 11 and validated eQMS platforms

Pre-validated eQMS platforms significantly reduce the compliance burden for organizations implementing electronic records and signatures. A platform vendor that provides a validation package, including Installation Qualification, Operational Qualification, and Performance Qualification documentation, which allows the customer organization to leverage vendor testing rather than conducting full custom validation from scratch.

However, vendor validation does not replace customer validation responsibilities. The customer organization is responsible for validating that the system is correctly configured and used for its specific intended use, that integrations with other systems do not compromise record integrity, and that all Part 11 controls function as expected in the production environment. Supplier qualification of the eQMS vendor, including review of the vendor’s quality system and validation methodology, is a prerequisite to relying on vendor-supplied validation documentation.

Cloudtheapp’s platform is built for FDA-regulated environments, with built-in audit trail functionality, role-based access control, electronic signature workflows meeting Part 11’s two-component requirement, and validation documentation support. The platform covers 60+ quality and compliance applications, from document control and CAPA to laboratory management and batch records, within a single validated environment, reducing the number of separate systems that each require individual Part 11 compliance assessment.

If your organization is evaluating electronic QMS platforms for Part 11 compliance, request a demo to review Cloudtheapp’s built-in compliance controls and validation approach.

Conclusion

21 CFR Part 11 compliance is not a one-time project; it is an ongoing operational discipline that requires validated systems, maintained access controls, reviewed audit trails, trained users, and current procedures. The organizations that consistently pass FDA inspections with clean Part 11 records are those that treat electronic record integrity as a quality system obligation, not a technology checkbox.

This checklist provides a starting framework for assessing compliance against the regulation’s core requirements. The most common inspection findings, specifically shared accounts, unreviewed audit trails, and unvalidated changes, are preventable through straightforward procedural and technical controls. Building those controls into the quality system from the time a system is first deployed is substantially less expensive than remediating them after an inspection finding has been issued.

]]>

This post created by and appeared first on Cloudtheapp

The IQ/OQ/PQ framework, installation qualification, operational qualification, and performance qualification, is the standard structure for executing that validation. FDA’s 21 CFR Part 11, EU Annex 11, and ISO 13485 Section 7.6 all require that computerized systems be validated, and all expect the IQ/OQ/PQ approach as the documented evidence of that validation.

FDA’s 2022 Computer Software Assurance (CSA) guidance updated the agency’s thinking: it shifted the emphasis from documentation volume toward risk-based testing that focuses validation effort on the system functions that matter most for patient safety and product quality. This guide explains the IQ/OQ/PQ framework, how CSA changes the approach, and what executing each protocol actually requires.

Why computer system validation matters

A computerized system that is not validated is a compliance liability on multiple fronts. Under 21 CFR Part 11, electronic records generated by an unvalidated system may not be accepted as equivalent to paper records. Under 21 CFR Part 820 (QMSR) and ISO 13485, using unvalidated software for quality-critical functions, document control, CAPA management, complaint handling, is itself a nonconformance. Under 21 CFR 211.68, pharmaceutical manufacturers must validate computer systems used in drug manufacturing and testing.

FDA warning letters and 483 observations for computer system validation failures are consistent: the most common findings are no validation at all, validation completed after the system went live, or validation protocols that were never fully executed.

The risk-based approach: GAMP 5 and FDA’s CSA guidance

GAMP 5 (Good Automated Manufacturing Practice, 5th edition) from ISPE is the industry-standard framework for risk-based computer system validation. It categorizes software by type, infrastructure software, non-configured commercial software, configured commercial software, custom software, and scales the validation effort to the category and the system’s impact on regulated activities.

FDA’s 2022 CSA guidance aligned with this risk-based philosophy. CSA distinguishes between “verification activities” (the technical testing that confirms the system works) and “documentation” (the records that demonstrate compliance). CSA’s message is that documentation should support verification, not replace it, validation time should be spent on testing functions that matter, not on scripted testing of vendor-provided features that have already been verified by the vendor.

In practice, the IQ/OQ/PQ structure remains the standard. What changes under CSA is the depth and formality of documentation relative to the system’s risk level. A low-risk infrastructure tool may require a streamlined validation package. A high-risk system used for GMP batch release or CAPA management requires more thorough testing and more comprehensive records.

The Validation Master Plan

Before executing individual IQ/OQ/PQ protocols, a Validation Master Plan (VMP) or equivalent planning document must define the overall approach. The VMP establishes:

The scope of systems subject to validation

The risk classification criteria used to determine validation depth

The organization’s overall validation lifecycle policy

Roles and responsibilities for validation activities

The standard format for validation protocols and reports

The change control and periodic review requirements for validated systems

Individual system validations reference the VMP. They do not need to re-establish the policy each time, they simply document how the policy is applied to the specific system being validated.

User Requirements Specification (URS)

Every computer system validation begins with a User Requirements Specification. The URS defines what the system must do, in business and regulatory terms, before any technical design decisions are made. It is the benchmark against which the system is tested in OQ and PQ.

A well-written URS distinguishes between requirements (what the system must do) and implementation details (how it does it). Requirements must be testable, vague requirements like “the system must be easy to use” cannot be validated. Specific requirements like “the system must require a reason for change whenever a document is revised” can be tested and confirmed.

The URS must capture 21 CFR Part 11 requirements explicitly: unique user IDs, password controls, audit trail with user identity, timestamp, and original/changed values, electronic signature binding, and system access controls. These are regulatory requirements, not vendor-optional features.

Installation Qualification (IQ)

IQ documents that the system has been installed correctly and that the installation environment meets the prerequisites for the system to function as specified. IQ is primarily a verification activity, it confirms facts about the installed state rather than testing system behavior.

What IQ covers

Software version verification: confirm the installed version matches the validated and approved version

Hardware inventory and specification check: confirm servers, workstations, and network infrastructure meet minimum requirements

Operating system and database version confirmation

Security configuration: user authentication settings, password policy settings, network security controls

Data backup and recovery procedures are in place and documented

System documentation inventory: vendor IQ documentation, configuration specifications, system architecture diagrams

Access control setup: confirm that the system’s user roles and permissions structure is installed as configured

IQ does not test whether the system works, it confirms that the foundation is in place for OQ testing to proceed. IQ failures typically involve missing documentation, version mismatches, or infrastructure components that do not meet specifications.

Operational Qualification (OQ)

OQ tests that the system functions as designed across its specified operating range and under both normal and boundary conditions. OQ verifies functional requirements from the URS, it tests the system’s behavior, not just its installation state.

OQ test design principles

Under FDA’s CSA guidance, OQ tests should focus on the system functions that carry the highest regulatory risk. For an eQMS, that means the CAPA workflow, the document approval chain, the electronic signature function, the audit trail, and the access control enforcement. It does not mean testing every dropdown menu and every report format.

Each OQ test script must include:

The specific function being tested, linked to the URS requirement it verifies

The preconditions (test data, user role, system state) before the test is executed

The step-by-step test procedure

The expected result, defined before the test is executed

Space for the actual result and a pass/fail determination

Tester identification and date, captured at the time of execution

OQ tests must include negative testing, attempts to perform actions that should be blocked by the system. An audit trail test that only confirms audit trail entries are created when records change does not test whether the audit trail can be modified or deleted. Negative testing closes that gap.

Key OQ areas for regulated systems

Audit trail: Verify that every create, modify, and delete action on regulated records generates a timestamped, user-attributed audit trail entry. Verify that the original value is retained and visible. Verify that audit trail entries cannot be modified or deleted by any user, including administrators.

Electronic signatures: Verify that signature prompts require password re-entry. Verify that the signed record links the signer’s identity, meaning, and timestamp. Verify that signatures cannot be applied to a different record or transferred.

Access control: Verify that users can only access and modify records consistent with their assigned role. Verify that unauthorized actions are blocked and generate an error, not a silent failure.

Workflow enforcement: Verify that controlled workflows (document approval, CAPA closure, deviation escalation) cannot be bypassed, that no user can skip a required step.

Performance Qualification (PQ)

PQ confirms that the validated system performs correctly in its actual production environment, with real users, real data, and real workloads. It bridges the gap between the controlled OQ environment and routine use.

PQ is often structured as user acceptance testing (UAT). It uses test scenarios drawn from actual business processes, not abstract functional tests, but real workflows executed by the people who will use the system daily. A PQ scenario for an eQMS might be: “A quality manager initiates a CAPA from a deviation record, assigns tasks to two corrective action owners, approves the corrective actions, and closes the CAPA. Verify that all workflow steps are enforced, that audit trail entries are generated at each step, and that the closed CAPA is locked against further modification.”

PQ test cases should cover the highest-volume and highest-risk processes. Edge cases and unusual scenarios are addressed in OQ. PQ focuses on confirming that the system supports the business processes it was implemented to replace or support.

Validation report and system release

Following IQ, OQ, and PQ execution, a Validation Summary Report documents the test results, any deviations encountered, the disposition of those deviations, and a formal conclusion that the system is validated and released for use. The report must be approved before the system goes live in production use.

Deviations from test scripts, unexpected results, failed tests, scope changes, must be documented as they occur and resolved through a formal deviation management process. A deviation that is discovered, silently corrected, and not recorded in the validation record is a data integrity failure, not a technical issue.

Change control and periodic review for validated systems

Validation does not end at system release. Validated systems must be controlled through a change management process that evaluates the impact of any change, software updates, configuration changes, new user role definitions, infrastructure changes, on the validated state. Changes that could affect validated functions require re-validation of the affected areas before implementation.

Periodic review is a separate requirement: at defined intervals (typically annually or biennially), the validated state of each system must be confirmed. The review assesses whether the system continues to be used as intended, whether any uncontrolled changes have occurred, whether there are outstanding deviations or open nonconformances, and whether the validation documentation remains current and complete.

Validation of a pre-validated eQMS platform

Many regulated companies use commercial off-the-shelf (COTS) eQMS platforms that are supplied with a vendor validation package, also called a pre-validation package, vendor qualification package, or Installation Qualification package from the vendor. This package documents the vendor’s own testing of the software’s standard functions.

A vendor validation package does not replace the customer’s validation obligation. The customer must still execute IQ to confirm correct installation in their specific environment, OQ to confirm that the configured system meets their specific URS requirements, and PQ to confirm that the system supports their specific business processes. The vendor package reduces the customer’s burden for testing standard vendor-provided functionality, but it does not cover the customer’s unique configuration or their specific regulatory requirements.

Cloudtheapp provides a complete validation package with every platform update, covering IQ documentation and standard functional testing for all 60+ applications. Customer organizations execute their OQ and PQ against their specific configuration and business processes, with Cloudtheapp’s validation documentation serving as the IQ foundation. The platform is built and maintained in compliance with FDA 21 CFR Part 11 and 21 CFR Part 11 electronic records and signature requirements.

To see how Cloudtheapp’s pre-validated platform reduces your CSV burden while meeting FDA and ISO 13485 requirements, request a demo.

Summary

Computer system validation through IQ, OQ, and PQ is a regulatory requirement for any system used in quality-critical or GMP functions. IQ confirms correct installation. OQ tests that the system functions as specified, with particular depth on audit trail, electronic signatures, access control, and workflow enforcement. PQ confirms the system performs correctly in the actual production environment with real users and real processes. FDA’s CSA guidance directs validation effort toward risk-based testing rather than documentation volume. Change control and periodic review keep validated systems in a validated state. A pre-validated commercial platform reduces the CSV burden, but the customer’s OQ and PQ remain their responsibility.

]]>

This post created by and appeared first on Cloudtheapp

This guide covers the GAMP 5 framework, the five software categories, what validation looks like in practice, and how modern pre-validated QMS platforms change the equation.

What is GAMP 5?

GAMP stands for Good Automated Manufacturing Practice. GAMP 5 is a guidance document published by the International Society for Pharmaceutical Engineering (ISPE) that provides a practical framework for validating automated and computerized systems used in GxP-regulated environments.

The current edition, GAMP 5 Second Edition, was released by ISPE in 2022. It updates the original 2008 publication to reflect the shift from traditional Computer System Validation (CSV) toward FDA's Computer Software Assurance (CSA) approach, which emphasizes critical thinking and risk-based validation over documentation volume.

GAMP 5 applies to any system that affects product quality, patient safety, or data integrity in regulated industries including pharmaceuticals, biotechnology, medical devices, and food production.

According to research published in PMC/NIH (2024), GAMP 5 provides the most widely adopted framework for computer system validation in life sciences, covering everything from infrastructure components to highly custom laboratory systems.

Why GAMP 5 matters for quality teams

FDA's 21 CFR Part 11 requires that electronic records and electronic signatures meet specific requirements for trustworthiness and reliability. EU GMP Annex 11 imposes similar requirements for computerized systems in European pharmaceutical manufacturing.

Neither regulation tells you precisely how to validate a system. GAMP 5 fills that gap. It gives validation teams a structured methodology that regulators recognize and inspectors expect to see referenced in validation documentation.

A system that lacks GAMP 5-aligned validation documentation is a liability during an FDA inspection or EU GMP audit. An FDA Form 483 observation for inadequate computer system validation is one of the most common findings in pharmaceutical and biotech facility inspections.

The five GAMP 5 software categories

GAMP 5 organizes software into five categories based on complexity and the degree of customization required. Each category has a corresponding validation approach. The higher the category number, the more complex the system and the more extensive the validation documentation.

Category 1: Infrastructure software

Category 1 covers operating systems, database engines, network software, and other infrastructure components that support GxP applications but do not directly process regulated data. Examples include Microsoft Windows, Oracle Database, and network management tools.

Infrastructure software requires qualification rather than validation. This typically means confirming that the software is properly installed, configured, and maintained, but full IQ/OQ/PQ protocols are not required.

Category 2: (Retired in GAMP 5 Second Edition)

Category 2 covered firmware in GAMP 4. The 2022 Second Edition retired this category and absorbed firmware into appropriate categories based on use context.

Category 3: Non-configured products (standard software)

Category 3 covers commercially available software used without configuration, such as word processors, spreadsheets used for non-critical calculations, or standard off-the-shelf tools. These products require limited validation, typically confirming installation qualification (IQ) and basic operational testing.

The key distinction is that Category 3 software has no configuration specific to the regulated environment. If a company starts configuring a Category 3 product extensively for GxP use, it moves toward Category 4 territory.

Category 4: Configured products

Category 4 is where most enterprise QMS software, LIMS systems, and manufacturing execution systems fall. These are commercially developed products that require configuration to meet the organization's specific processes and data requirements.

For Category 4 systems, GAMP 5 requires a risk-based validation approach including user requirements specifications (URS), configuration specifications, and IQ/OQ/PQ qualification testing.

As noted in IntuitionLabs' GAMP 5 categories guide, the key principle for Category 4 is that a competent vendor plus thorough IQ/OQ/PQ documentation provides the validation foundation. The vendor's development lifecycle, testing evidence, and validation package support your organization's qualification.

Category 5: Custom software

Category 5 covers software developed specifically for the regulated company, including bespoke laboratory systems, custom manufacturing control applications, and internally developed quality management tools.

Custom software carries the highest validation burden because there is no vendor validation package to leverage. The organization must validate the full software development lifecycle, including requirements management, design review, code testing, and PQ testing under realistic production conditions.

The GAMP 5 validation lifecycle

Regardless of software category, GAMP 5 describes a consistent validation lifecycle that mirrors the broader V-model used in regulated software development.

User requirements specification (URS)

The URS defines what the system must do from a user and business perspective. Every requirement should be testable and traceable. A strong URS is the foundation of every downstream validation activity.

Functional and design specifications

For configured and custom systems, functional specifications translate user requirements into system behavior descriptions. Design specifications detail how the system will be built or configured to meet those functional requirements.

Installation qualification (IQ)

IQ verifies that the system has been installed correctly in its intended environment. This includes confirming software version, hardware specifications, network configuration, and security settings match what was specified.

Operational qualification (OQ)

OQ tests that the system operates as intended under normal and boundary conditions. OQ testing follows pre-approved test scripts with defined expected results. Testers document actual results and any deviations.

Performance qualification (PQ)

PQ demonstrates that the system performs reliably under production conditions using realistic data and workflows. PQ is often the final validation activity before a system goes live in a regulated environment.

Traceability

A complete GAMP 5 validation package includes a requirements traceability matrix (RTM) linking every URS requirement to one or more test cases in IQ, OQ, or PQ. The RTM proves that every requirement has been tested and met.

What GAMP 5 Second Edition (2022) changed

The 2022 revision introduced several significant updates aligned with FDA's CSA guidance:

Risk-based approach: The new edition strengthens the emphasis on focusing validation effort on critical functions. Low-risk functions may require minimal documentation while high-risk functions need thorough testing evidence.

Critical thinking over templates: GAMP 5 Second Edition explicitly discourages a checkbox approach. Validation teams should apply judgment rather than produce documentation for its own sake.

Agile and iterative development: The 2022 edition accommodates modern software development approaches, including agile sprints and iterative configuration, rather than assuming a purely waterfall development model.

Supplier assessment: The updated guidance places greater emphasis on assessing the supplier's development practices, quality management system, and validation package quality. A strong vendor QMS reduces the validation burden on the regulated company.

GAMP 5 and pre-validated QMS platforms

One of the most practical developments in recent years is the availability of pre-validated, cloud-based QMS platforms built specifically for GxP-regulated industries. These platforms are developed under a supplier quality management system, maintain complete validation documentation packages, and provide IQ/OQ evidence with each release.

For a Category 4 QMS platform, a pre-validated product means your organization receives a vendor validation package that covers the software development lifecycle, release testing, and qualification evidence. Your team's responsibility narrows to confirming installation in your environment (IQ), running OQ tests on your configured processes, and conducting PQ with your actual data.

This approach can reduce validation timelines from months to weeks. Rather than building a validation package from scratch, your quality team reviews and augments vendor documentation with organization-specific evidence.

Cloudtheapp is an FDA-validated, cloud-based QMS with 60+ applications designed for regulated industries. The platform provides a complete validation package with every release, including IQ/OQ/PQ documentation aligned with GAMP 5 and FDA CSA guidance. Validation teams get a pre-qualified baseline and configure only what their process requires.

To see how Cloudtheapp's pre-validated platform works in practice, request a demo and walk through the validation package with a solutions engineer.

Common GAMP 5 mistakes quality teams make

Applying the same validation intensity to every system: A word processor and a LIMS have very different risk profiles. Applying Category 5 validation effort to a Category 3 system wastes time without adding compliance value.

Writing URS requirements that are untestable: "The system must be easy to use" cannot be tested. Every URS requirement must map to a specific, verifiable test condition.

Treating GAMP 5 as a checklist: GAMP 5 is a risk-based framework, not a mandatory template set. Regulators increasingly distinguish between teams that understand validation rationale and teams that produce paper without judgment.

Skipping supplier assessment: For Category 4 systems, your supplier's development practices directly affect your validation burden. A vendor with a well-documented quality system and a strong validation package is a compliance asset.

Failing to maintain validation through change control: Validation is not a one-time event. Every significant change to a validated system requires impact assessment, and affected tests must be re-executed and documented.

Frequently asked questions

Who does GAMP 5 apply to?

GAMP 5 applies to any organization in a GxP-regulated industry that uses automated or computerized systems affecting product quality, patient safety, or data integrity. This includes pharmaceutical manufacturers, biotech companies, medical device manufacturers, and contract laboratories.

Is GAMP 5 required by FDA?

GAMP 5 is not a regulation. FDA does not mandate GAMP 5 by name. However, the principles it embodies, particularly for 21 CFR Part 11 compliance and computer system validation, align directly with FDA expectations. Most regulated companies reference GAMP 5 as the methodology underlying their validation program.

How does GAMP 5 relate to FDA's Computer Software Assurance guidance?

FDA's 2022 Computer Software Assurance (CSA) guidance aligns closely with GAMP 5 Second Edition's risk-based, critical-thinking approach. Both frameworks move away from documentation-intensive validation toward evidence-based assurance focused on critical functions.

What documents make up a GAMP 5 validation package?

A complete GAMP 5 validation package typically includes a validation plan, URS, functional specifications, design specifications, IQ/OQ/PQ protocols and reports, a traceability matrix, and a validation summary report. Supplier documentation supplements organization-generated materials for Category 4 systems.

How long does GAMP 5 validation take?

Timeline varies by category and system complexity. A Category 3 tool may validate in days. A Category 4 enterprise QMS typically takes six to twelve weeks with a pre-validated vendor package. A Category 5 custom system may take six months to a year.

This post created by and appeared first on Cloudtheapp

GAMP 5 is the internationally accepted guidance for validating computerized systems in GxP-regulated environments, pharmaceuticals, biotech, medical devices, and food. Published by ISPE, it gives regulated companies a risk-based, scalable framework for determining how much validation work each software system requires. The Second Edition, published in July 2022, introduced agile development support, updated cybersecurity and cloud guidance, and aligned with FDA’s Computer Software Assurance (CSA) guidance. Understanding GAMP 5 software categories and lifecycle principles is the starting point for any GxP computer system validation program.

What GAMP 5 is

GAMP stands for Good Automated Manufacturing Practice. GAMP 5 is the fifth edition of the guidance originally developed in 1991 by a group of UK pharmaceutical engineers working to meet FDA expectations on automated manufacturing systems. ISPE (International Society for Pharmaceutical Engineering) has published and maintained the guidance since the formal partnership began in 1995.

The full title of the current version is “GAMP® 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition),” published in July 2022 by ISPE. The guidance is advisory, it carries no direct legal obligation. However, the FDA, EMA, and other regulatory agencies worldwide reference and respect GAMP 5 as the industry standard for computer system validation (CSV).

According to ISPE, GAMP 5 aims to deliver a cost-effective framework of good practice to ensure that computerized systems are effective, of high quality, and compliant with applicable regulatory requirements.

Why regulated companies follow GAMP 5

GAMP 5 addresses a practical problem: not all software systems in a regulated facility carry the same risk to patient safety, product quality, or data integrity. An operating system that runs a desktop computer carries different risk than a manufacturing execution system that controls batch production. Treating both with identical validation rigor is wasteful. Treating the manufacturing system too casually creates regulatory exposure.

GAMP 5 solves this with a risk-based categorization system and a lifecycle framework that scales validation effort to actual system risk. The result is a validation program that is defensible in an FDA inspection, proportional to the criticality of each system, and practical enough to execute without consuming the entire quality team’s capacity.

The guidance applies across GxP domains, Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Distribution Practice (GDP), and pharmacovigilance. It works in conjunction with 21 CFR Part 11 for electronic records and electronic signatures, EU GMP Annex 11, ISO 13485, and ISO 14971.

The four GAMP 5 software categories

The software category system is the practical core of GAMP 5. Each category defines the level of validation evidence required. The Second Edition retained the same four active categories as the first edition. Category 2 (firmware), which appeared in the earlier GAMP 4 guide, was removed.

Category 1: Infrastructure software

This covers operating systems, databases, middleware, network software, and other base-layer technology. Category 1 software is generally not subject to specific functional verification, the focus is on installation qualification and maintaining the system in a known, controlled state. Examples include Windows Server, Oracle Database, and network monitoring tools.

Category 3: Non-configured products

These are commercial off-the-shelf (COTS) software products used without any configuration specific to the regulated use. The software performs a defined function that does not vary based on user settings. Validation focuses on confirming that the software performs its intended function in the user’s environment. Examples include standard statistical analysis software or laboratory equipment software used without customization.

Category 4: Configured products

This is the most common category in regulated pharmaceutical and medical device environments. Category 4 covers commercial software that is configured to meet the user’s specific requirements, but where configuration stays within the limits the software developer designed. ERP systems, laboratory information management systems (LIMS), and quality management systems fall into this category. Validation covers installation qualification, operational qualification, and confirmation that the specific configuration performs as specified in the user requirements.

Category 5: Custom applications

These are software systems built specifically for the regulated company’s use, either developed in-house or by a third party on a custom basis. Category 5 systems carry the highest validation burden because there is no supplier validation package to leverage. Validation must cover design specifications, code review, unit testing, integration testing, and full IQ/OQ/PQ protocols. Custom manufacturing control systems and bespoke data acquisition applications are typical examples.

For eQMS platforms like Cloudtheapp, which are commercial SaaS products configured to the customer’s quality processes, GAMP Category 4 validation applies. The supplier (Cloudtheapp) provides a validation package covering the platform itself; the customer’s validation effort focuses on configuration qualification and user acceptance testing for their specific setup.

The GAMP 5 validation lifecycle

GAMP 5 organizes validation work around four lifecycle stages: Concept, Project, Operations, and Retirement.

Concept

At this stage, the regulated company identifies the need for a computerized system, defines initial requirements, and assesses potential solutions. The Concept stage falls largely outside the GAMP validation scope for the system itself, but it establishes the foundation for everything that follows, particularly the User Requirements Specification (URS) that will drive all subsequent validation activities.

Project

This is where the system is designed, developed, deployed, and assessed for GxP compliance. The first edition of GAMP 5 relied on the V-model (a linear development approach that maps specification activities to corresponding verification tests). The Second Edition added full support for agile development methodologies, recognizing that SaaS platforms, AI systems, and machine learning applications operate on continuous release cycles that the traditional waterfall model cannot accommodate.

Under the agile approach, validation documentation evolves alongside the system, with testing integrated into each development sprint rather than deferred to a final validation phase. The core principle is the same, documented evidence that the system performs as intended, but the mechanism adapts to the development model.

Operations

This is typically the longest lifecycle stage. The system is in active use, and the objective is to maintain it in a validated state. Key activities in the Operations phase include change control, periodic review, audit trail review, and incident management. Every change to a validated system must be assessed for impact on the validated state, documented, and tested if the impact assessment identifies risk.

Retirement

When a system reaches end of life, the Retirement stage addresses data migration or archival, system decommissioning, and documented evidence that regulated data has been preserved in a retrievable format. GAMP 5 does not define a separate Retirement stage formally, but the guidance in the Operations stage covers the planning and execution required.

The five key GAMP 5 principles

The GAMP 5 guidance rests on five principles that shape how validation work is planned and executed.

Product and process knowledge. Validation decisions should be driven by genuine understanding of what the system does and how it affects GxP activities, not by following a documentation template mechanically. Risk-based decisions require knowing what matters.

Lifecycle approach. Validation is not a one-time event at system go-live. It extends across the entire system lifecycle, from concept through retirement. This means periodic reviews, change control, and ongoing evidence of controlled operation.

Scalable. The depth of validation should match the system’s risk profile. A low-risk Category 1 infrastructure component does not require the same documentation depth as a Category 5 custom application that controls a manufacturing process. GAMP 5 explicitly supports reduced documentation where the risk justifies it.

Quality risk management. Risk assessment determines which system functions require the most validation attention. GAMP 5 2nd Edition reinforced the shift toward testing-focused validation over documentation-heavy approaches, supporting exception-based reporting where a simple “Pass” is sufficient for tests that execute as expected.

Leverage supplier activity. When a supplier provides a validated platform with supporting documentation, installation guides, validation packages, release notes, test evidence, the regulated company can leverage that documentation rather than duplicating the work. This is the foundation of the supplier leverage model for Category 4 SaaS platforms.

GAMP 5 and FDA’s Computer Software Assurance guidance

The 2022 Second Edition of GAMP 5 explicitly aligned with FDA’s September 2022 draft guidance on Computer Software Assurance (CSA) for Production and Quality System Software. The FDA’s CSA guidance represents a philosophical shift away from documentation-heavy validation toward testing-critical-thinking-driven assurance.

The core message in both documents: validation effort should focus on critical functions that affect patient safety, product quality, and data integrity. Generating paper to satisfy a checklist, without genuine testing or critical thinking, provides no real assurance and diverts resources from meaningful quality work.

For quality teams, this alignment means GAMP 5 and FDA expectations are now more consistent than at any point in the history of computer system validation. Teams that follow GAMP 5 principles are building validation programs that FDA inspectors increasingly expect to see.

GAMP 5 in practice: what your validation program should include

A GAMP 5-compliant validation program for a Category 4 system typically includes:

A User Requirements Specification (URS) that documents what the system must do from the regulated company’s perspective, with traceability to GxP requirements.

A supplier assessment that evaluates the vendor’s quality management system, development practices, and available validation documentation. For cloud-based eQMS platforms that maintain a pre-validated environment and update documentation with each release, this step is significantly reduced.

An Installation Qualification (IQ) that confirms the system was installed correctly in the intended environment, per the supplier’s specifications.

An Operational Qualification (OQ) that confirms the system functions as specified under defined conditions.

A Performance Qualification (PQ) / User Acceptance Testing (UAT) that confirms the system meets business requirements in actual use conditions.

Change control and periodic review procedures that maintain the validated state across the Operations lifecycle stage.

How an eQMS supports GAMP 5 validation

Cloudtheapp’s platform is a pre-validated, cloud-based eQMS built on GAMP Category 4 validation principles. The platform runs on AWS with a supplier-maintained validation package that covers each release, including installation qualification documentation, test evidence, and release notes, all provided to customers to support their own validation obligations.

The 60+ applications on the Cloudtheapp platform, covering document control, audit trail management, CAPA, supplier qualification, and change management, are designed to operate in 21 CFR Part 11-compliant environments, with electronic records and signatures that meet FDA data integrity expectations.

For quality teams building or refreshing their computer system validation program for a new eQMS, Cloudtheapp provides the supplier documentation package, validation support, and a pre-configured validation template set that dramatically reduces the time required to complete IQ/OQ/PQ documentation.

See how Cloudtheapp supports GAMP 5-compliant validation

Common GAMP 5 questions

Is GAMP 5 mandatory?

No. GAMP 5 is advisory guidance published by ISPE, not a regulatory requirement. However, it is the globally recognized standard for GxP computer system validation, and FDA inspectors regard GAMP 5-based validation programs as evidence of a mature quality system approach.

What changed in GAMP 5 Second Edition?

The 2022 Second Edition added agile development support, updated guidance on cybersecurity and cloud computing, addressed AI and machine learning applications, incorporated Blockchain/distributed ledger systems, and aligned explicitly with FDA’s Computer Software Assurance draft guidance. The software categories themselves remained the same.

What is the difference between CSV and CSA?

Computer System Validation (CSV) is the traditional term for the documented process of proving a GxP system performs as intended. Computer Software Assurance (CSA) is the FDA’s more recent framing, which emphasizes critical thinking and testing over documentation generation. GAMP 5 Second Edition aligns with both framings and supports transitioning from documentation-heavy CSV to more risk-proportional CSA approaches.

Does GAMP 5 apply to cloud-based systems?

Yes. The Second Edition includes updated guidance specifically addressing cloud computing, SaaS, and infrastructure as a service (IaaS). The key principle for cloud systems is clarifying responsibilities between the cloud service provider and the regulated customer, particularly around data security, access control, change management, and business continuity.

Conclusion

GAMP 5 gives regulated companies a practical, risk-based structure for validating the software systems that support GxP activities. The software category system scales validation effort to actual risk. The lifecycle framework ensures validation is not a one-time event but a maintained state across the system’s operational life. The Second Edition’s alignment with FDA’s CSA thinking makes GAMP 5 more current and defensible than ever.

For organizations deploying or upgrading an eQMS, applying GAMP 5 principles from the outset, starting with a clear URS, a structured supplier assessment, and a proportional IQ/OQ/PQ program, builds a validation record that holds up in an inspection and sustains the validated state over time.

Request a demo to see how Cloudtheapp supports GAMP 5-compliant validation

This post created by and appeared first on Cloudtheapp